Quality documentation concerning biological investigational medicinal products in clinical trials
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
On 3 May, the European Comission published the "Guideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials".
The guideline is related to proteins and polypeptides, their derivatives and products of which they are components and addresses the specific documentation requirements on the biological, chemical and pharmaceutical quality of IMPs containing biological / biotechnology derived substances in cases where no 'simplified IMPD' is submitted.
Amongst others, the document includes in its first part necessary information on manufacturing, characterisation, reference standards and stability of active substances as well as investigational medicinal products currently tested. The second part are four appendices with the focus on
- Facilities and Equipement
- Adventitious agents safety evaluation
- Excipients
- Solvents for reconstitution and diluents
The third part of the guideline covers a non-exhaustive list of typically 'substantial' amendments.
Please see the complete "Guideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials".
Author
Axel H. Schroeder
CONCEPT HEIDELBERG (a service provider entrusted by the ECA Foundation)
Related GMP News
11.12.2025Insurance Review in Phase 1 Clinical Trials
11.12.2025EMA Publishes Comments on ICH E21
27.11.2025Final ICH M14 Guideline on the Use of RWD for Safety Assessment
25.11.2025Clinical Trials: BMG publishes Standard Contractual Clauses Ordinance
04.11.2025UK Clinical Trials Regulations: Six-Month Countdown
04.11.2025Clinical Trials - Update on the CTIS